Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
Globenewswire·2025-11-10 16:45
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medical need in difficult-to-control hypertension Allschwil, Switzerland – November 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypertension title ...